Promoted Content Promoted Content

X

Find FDA Investigational New Drug (IND) Submissions for Psychiatry/Psychology in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PF614

            Therapeutic Area: Psychiatry/Psychology Product Name: PF614-MPAR

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: NATIONAL INSTITUTE DRUG ABUSE

            Deal Size: $8.0 million Upfront Cash: Undisclosed

            Deal Type: Funding July 08, 2021

            Details:

            PF614-MPAR™ is designed as an extended-release oxycodone prodrug with both trypsin-activated abuse protection (TAAP) and overdose protection through multi-pill abuse resistance (MPAR™) technology.